Clinical Trials Logo

Clinical Trial Summary

This is a randomized, placebo-controlled, multiple dose escalation study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR0534. The study will be conducted with dose of 5 mg, 10mg and 25 mg. Chinese Type 2 Diabetic patients will be randomized in each cohort to receive the study drug or placebo.

Clinical Trial Description


Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

NCT number NCT03006159
Study type Interventional
Source Jiangsu HengRui Medicine Co., Ltd.
Status Completed
Phase Phase 1
Start date March 2015
Completion date March 2016

See also
  Status Clinical Trial Phase
Completed NCT01049750 - Prevalence and Risk Factors of Erectile Dysfunction in Type 2 Diabetic Patients N/A
Not yet recruiting NCT03987308 - Comparing the Efficacy and Safety Between Short-term Continuous Subcutaneous Beinaglutide Injection and Continuous Subcutaneous Insulin Infusion (CSII) for Newly Diagnosed Type 2 Diabetes N/A
Completed NCT01049321 - The Effect of DASH Diet on the Cardiometabolic Risks and Hepatic Function Among Type 2 Diabetic Patients Phase 4
Completed NCT02164578 - Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Cardiovascular Disease Phase 3
Completed NCT00941148 - Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin Phase 4